NVO · Healthcare
Novo-Nordisk A S
30/100
Smart-money confidence1 of 3 sources positive
Weak — few signals
No standout activity across the feeds we track.
Hedge funds
40
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Market cap
$201.1B
Industry
Drug Manufacturers - General
Sector
Healthcare
Exchange
NYSE
About NOVO-NORDISK A S
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin…
Who's behind the signal
Every informed buyer we can see on NVO, across all three feeds.
Hedge funds · 7
Tudor Investment (Paul Tudor Jones)
Increased +88%
D.E. Shaw & Co
Increased +141%
AQR Capital Management
Increased +28%
Markel Group (Tom Gayner)
Unchanged
Citadel Advisors
Decreased −63%
Millennium Management (Englander)
Decreased −13%
+1 more in the full breakdown below ↓
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Congressional trades · 6 on record
Disclosures from 2017-09-08 to 2021-09-16
The newest disclosure we hold for this stock is 2021-09-16.
That is the end of our data, not necessarily the end of the trading — our
bulk STOCK Act archive stops there and newer filings arrive through a
separate live feed. Treat the absence of recent rows as “not covered”,
not as “no trades”.
| Trade date | Member | Chamber | Action | Amount |
|---|---|---|---|---|
| 2021-09-16 | Katherine M. Clark · D-MA | House | Sold | $1,001 - $15,000 |
| 2020-11-05 | Katherine M. Clark · D-MA | House | Bought | $1,001 - $15,000 |
| 2020-04-02 | Thomas R. Carper · D-DE | Senate | Bought | $1,001 - $15,000 |
| 2020-02-20 | Mikie Sherrill · D-NJ | House | Sold | $1,001 - $15,000 |
| 2019-03-11 | Shelley Moore Capito · R-WV | Senate | Sold | $1,001 - $15,000 |
| 2017-09-08 | Shelley Moore Capito · R-WV | Senate | Bought | $1,001 - $15,000 |
Not a model pick — but on our radar.
NOVO-NORDISK A S isn't in the top-10 model right now, but 7 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
7
Investors
0
New positions
3
Increasing
3
Decreasing
1
Unchanged
Price History
Loading price data...
Return:
High:
Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.2×
% of portfolio
0.1%
Position change
+88%
0.1% of Tudor Investment's portfolio
Trust weight: 1.0×
% of portfolio
0.1%
Position change
+141%
0.1% of D.E. Shaw & Co's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+28%
0.0% of AQR Capital Management's portfolio
Trust weight: 1.4×
% of portfolio
1.1%
Position change
—
1.1% of Markel Group's portfolio
Trust weight: 1.0×
% of portfolio
0.1%
Position change
−63%
0.1% of Citadel Advisors's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−13%
0.0% of Millennium Management's portfolio
Trust weight: 1.4×
% of portfolio
0.0%
Position change
−81%
0.0% of Baillie Gifford & Co's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to NOVO-NORDISK A S
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell NOVO-NORDISK A S or any security.
订阅每周更新
我们每周会把巴菲特、达利欧、阿克曼以及另外 47 位传奇投资人正在买入的股票发送给你 — 免费，直接来自他们的 SEC 申报文件。
永久免费 · 无垃圾邮件 · 随时退订